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a b s t r a c t
Objective: The levels of leptin, a major regulator of lipid metabolism, may increase in obesity,
and contribute to the development of metabolic syndrome. Leptin is produced by adipose
tissue and is a peptide hormone, which has strong association with obesity, elevated
cardiovascular risk, and morbidity. The present study was designed to evaluate the relation-
ships between leptin levels, obesity, and cardiovascular risk factors in men with acute
myocardial infarction.
Methods and results: Twenty-four obese and twenty-three nonobese male patients, who had
experienced their ﬁrst myocardial infarction, were included in the study. Their leptin levels,
biochemical parameters, and anthropometric measures were obtained. Mean leptin levels
were signiﬁcantly higher in the obese group compared to the nonobese group (2.53 ng/mL
versus 1.23 ng/mL; p < 0.01). Leptin levels correlated positively with anthropometric mea-
surements, triglyceride, fasting glucose, C-reactive protein, and uric acid levels, and nega-
tively with high-density lipoprotein cholesterol levels.
Conclusion: Findings indicate high leptin levels to be positively correlated with obesity and
diastolic blood pressure in male patients with myocardial infarction.
# 2015 Cardiological Society of India. Published by Elsevier B.V. All rights reserved.
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Obesity is associated with a high risk of developing cardiovas-
cular (CV) and metabolic diseases, such as hypertension,
coronary atherosclerosis, myocardial hypertrophy, diabetes,* Corresponding author.
E-mail address: aysenhelvaci@superonline.com (A. Helvaci).
http://dx.doi.org/10.1016/j.ihj.2015.07.032
0019-4832/# 2015 Cardiological Society of India. Published by Elseviedyslipidemia, and increased CV morbidity and mortality.1
Leptin is a 16-kDa polypeptide (167 amino acids) hormone
synthesized and secreted into the circulation primarily by white
adipocytes.2,3 There is a strong relationship between body fat
mass and the amount of synthesized and secreted leptin.4,5
Leptin is considered to be an antiobesity hormone. The ﬁrstr B.V. All rights reserved.
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weight and fat deposition through its effects on hypothalamic
receptors, which leads to appetite inhibition, as well as its
effects on metabolic rate stimulation and thermogenesis.2,3
Leptin levels decrease during fasting and increase after several
days of overfeeding, in a mechanism that helps to regulate
energy balance in humans. Thus, increased leptin concentra-
tions would be expected to correlate with decreased weight.
However, serum leptin levels are in fact strongly correlated with
body fat mass in obese individuals. Recent studies suggest the
existence of an endogenous leptin-resistance mechanism in
obesity6 that may explain this unexpected correlation.
In obesity, elevated leptin levels are not sufﬁcient to prevent
disturbances in energy balance, suggesting that obese people
are leptin-resistant.7 Alternatively, another possibility is that
nonleptin-mediated mechanisms play a more powerful role
than leptin under the altered physiological conditions present
in obesity. Obesity is associated with increased sympathetic
nerve activity, and leptin, partly by increasing renal sympathet-
ic nerve activity, has been proven to participate in autonomic
nervous system control. Therefore, the contribution of leptin to
sympathetic activation in a leptin-resistant state, like obesity, is
contradictory. This has led to the novel concept of selective
leptin resistance, in which resistance appears to be primarily
limited to the metabolic (satiety and weight-reducing) functions
of leptin, sparing the other functions in obese individuals.8
It has been suggested that leptin could be an important link
between obesity and the development of CV diseases.9 This
might be mediated through various effects of leptin, including
effects on blood pressure,10 platelet aggregation,11 formation of
arterial thrombosis,12 and inﬂammatory vascular response.13
High levels of leptin are believed to be associated with reduced
arterial distensibility, an index of circulatory function, and
leptin is involved in the pathogenesis of the atherosclerotic
process through mechanisms other than vascular relaxation.14
Leptin has also been shown to promote angiogenesis, regulate
osteoblastic differentiation, enhance the calciﬁcation of vascu-
lar cells, and potentiate prothrombotic platelet aggregation
through a novel leptin receptor mechanism.11
Several studies have shown leptin to be a predictor of
myocardial infarction, coronary events, and stroke, indepen-
dent of body mass index (BMI).15,16 Plasma leptin was observed
to be higher in individuals with a paternal history of premature
myocardial infarction than in those without family history of
CV events.17 Plasma leptin was also higher in male patients,
who subsequently developed ﬁrst-ever myocardial infarction
than in control subjects.16
The aim of the present study was to assess the relation-
ships between blood leptin concentrations and several
anthropometric parameters and CV risk factors in obese and
nonobese men with acute myocardial infarction (AMI) treated
with primary coronary intervention (PCI).
2. Methods
2.1. Study population
The study subjects included 24 obese male patients and 23 age-
matched nonobese men as the control group, who experiencedtheir ﬁrst acute myocardial infarction. Patients who had
previous ischemic heart disease, atrial ﬁbrillation, bundle
branch block, and signiﬁcant valvular heart disease, or who
were >65 years of age, were excluded from the study.
Ethical approval was taken from local ethics committee.
Anthropometric measurements, clinical deﬁnitions, and
treatment.
AMI was diagnosed on the basis of symptoms, electrocar-
diographic signs, and elevation of myocardial injury markers.
A BMI of30, calculated asbody weightdivided by the square of
height (kg/m2), was used as the cutoff value for obesity. Patients
with a BMI <25 were designated as nonobese. Weight and height
were measured on the third or fourth day after admission, while
the subjects were fasting and wearing only their undergarments.
Waist circumference (WC), a measure of abdominal subcutane-
ous and visceral fat, was measured at the widest diameter
between the xiphoid process of the sternum and the iliac crest.
Hip circumference (HC), representing subcutaneous fat alone,
was measured at the widest diameter over the greater
trochanters. From these measurements, the waist-to-hip ratio
(WHR) was calculated. Systolic and diastolic blood pressures
(SBP, DBP) were measured before blood sampling.
2.2. Laboratory measurements
C-reactive protein (CRP) and uric acid levels were assessed as
part of a complex analysis of the blood samples taken upon
admission to the hospital. Fasting blood glucose levels, lipid
proﬁle and leptin levels were determined from the blood
drawn the following day. Plasma samples taken for leptin
concentration measurement were frozen at 70 8C, until
analysis with a sandwiched enzyme-linked immunosorbent
assay (ELISA) (ELx 800 Absorbance Microplate Reader [BioTek,
Winooski, USA] and Assay Max Human Leptin ELISA Kit
[Assaypro, St. Charles, MO, USA]).
2.3. Statistical analysis
Statistical analysis was performed using Statistical Package for
the Social Sciences (SPSS) for Windows (version 15.0; SPSS Inc.,
Chicago, IL, USA). Descriptive statistics were expressed as
mean  standard deviation. Variables were log-transformed
before statistical analysis, if necessary. Comparison between
the two groups was performed using the two-tailed, nonpaired
student's t-test or the Mann–Whitney test, as appropriate.
Categorical variables were presented as numbers or percen-
tages, and were analyzed using the chi-square test. Associa-
tion between the parameters was assessed using the
Spearman correlation coefﬁcient. A p value <0.05 was
considered statistically signiﬁcant.
3. Results
The proportion of patients with hypertension and smoking
were similar in the two groups, as were SBP levels. The
proportion of patients with high-density-lipoprotein choles-
terol (HDL-CH) <40 mg/dl, total CH >200 mg/dl, and triglycer-
ides (TG) >150 mg/dl were signiﬁcantly higher in the obese
group than in the control group, as were the anthropometric
Table 1 – Clinical characteristics and anthropometric measurements for the study participants.
Obese [n = 24] Nonobese [n = 23] p value
Mean (SD) Mean (SD)
Age 48.5 (11.4) 55.8 (8.8) 0.027
n (%) n (%)
Smoking 19 (79.2) 19 (82.6) 1.000
Hypertension 15 (62.5) 9 (39.1) 0.109
Mean (SD) Mean (SD)
Systolic blood pressure (SBP) 145.7 (26.4) 134.7 (28.3) 0.176
Diastolic blood pressure (DBP) 87.9 (17.6) 71.4 (27.5) 0.018
n (%) n (%)
Total cholesterol > 200 mg/dl 14 (58.3) 4 (17.4) 0.004
LDL cholesterol > 100 mg/dl 17 (70.8) 12 (52.2) 0.188
HDL cholesterol < 40 mg/dl 15 (62.5) 7 (30.4) 0.028
Triglycerides (TG) > 150 mg/dl 17 (70.8) 4 (17.4) <0.001
Mean (SD) Mean (SD)
Body mass index (kg/m2) 31.5 (2.1) 24.0 (1.3) <0.001
Waist circumference (cm) 111.3 (13.7) 91.7 (11.9) <0.001
Hip circumference (cm) 106.9 (10.1) 92.1 (15.7) <0.001
Waist-to-hip ratio 1.04 (0.06) 0.97 (0.05) <0.001
Table 2 – Biochemical parameters in the study groups.
Obese [n = 24] Nonobese [n = 23] p
Mean (SD) Mean (SD)
Fasting glucose (mg/dl) 167.5 (85.2) 138.8 (58.7) 0.142
Total cholesterol (mg/dl) 206.8 (48.3) 160.4 (45.8) 0.002
LDL-cholesterol (mg/dl) 135.9 (42.5) 102.7 (38.0) 0.007
HDL-cholesterol (mg/dl) 37.7 (5.7) 44.9 (12.7) 0.018
Triglycerides (mg/dl) 185.8 (68.2) 98.7 (43.1) <0.001
C-reactive protein (mg/dl) 26.6 (40.3) 20.6 (22.1) 0.941
Uric acid (mg/dl) 5.8 (1.4) 4.5 (1.6) 0.009
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characteristics and the anthropometric measurements for
the obese and nonobese patients are shown in Table 1.
In obese patients, all biochemical parameters were higher
except fasting glucose and CRP levels. The mean values of the
biochemical parameters assessed are presented in Table 2.
The mean leptin level in obese patients (2.53 ng/mL) was
signiﬁcantly higher than the mean leptin level in nonobese
patients (1.23 ng/mL; p < 0.001) (Fig. 1). There was a positive
correlation between leptin and the anthropometric measure-
ments (Table 3).
The relationship of leptin and anthropometric measure-
ments to obesity-related risk factors is shown in Table 4.Fig. 1 – Mean leptin values in obese and nonobese groups.Leptin was only positively correlated with DBP (p = 0.040,
r = 0.301). There were also positive correlations between BMI
and DBP, total CH, low-density-lipoprotein CH (LDL-CH), TG,
and uric acid, whereas there was an inverse correlation
between BMI and HDL-CH. In addition, WC and HC exhibited
positive correlations with fasting blood glucose, total-CH, LDL-
CH, and TG. Finally, WHR had a positive correlation with
fasting blood glucose and TG.
4. Discussion
The question of whether leptin, which has an important role in
obesity etiology, has a direct or indirect effect on coronary artery
disease has been previously studied.18 In the present study, we
analyzed the relationship between leptin, CV risk factors, andTable 3 – Correlation between leptin and anthropometric
measurements.
Anthropometric measurements Leptin
rho p
BMI (kg/m2) 0.527 <0.001
WC (cm) 0.579 <0.001
HC (cm) 0.430 0.003
WHR 0.633 <0.001
Table 4 – The relationship of leptin and anthropometric measurements to obesity-related risk factors.
Leptin BMI (kg/m2) WC (cm) HC (cm) WHR
SBP (mmHg)
rho 0.166 0.137 0.041 0.002 0.008
p 0.264 0.357 0.785 0.988 0.959
DBP (mmHg)
rho 0.301 0.307 0.151 0.111 0.143
p 0.040 0.036 0.310 0.457 0.337
Fasting glucose (mg/dl)
rho 0.141 0.148 0.381 0.296 0.309
p 0.345 0.322 0.008 0.044 0.034
Total CH (mg/dl)
rho 0.240 0.448 0.337 0.318 0.275
p 0.104 0.002 0.020 0.029 0.061
LDL-CH (mg/dl)
rho 0.153 0.447 0.318 0.325 0.240
p 0.304 0.002 0.029 0.026 0.104
HDL-CH (mg/dl)
rho 0.218 0.291 0.120 0.117 0.120
p 0.140 0.048 0.423 0.433 0.422
TG (mg/dl)
rho 0.248 0.612 0.480 0.432 0.405
p 0.093 0.000 0.001 0.002 0.005
CRP (mg/dl)
rho 0.092 0.078 0.169 0.225 0.054
p 0.538 0.600 0.255 0.128 0.720
Uric acid (mg/dl)
rho 0.269 0.357 0.207 0.134 0.215
p 0.068 0.014 0.164 0.367 0.146
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AMI. The leptin levels of the obese group were found to be
signiﬁcantly higher than that of the nonobese group. In previous
studies19 conducted on patients with coronary heart disease
(CHD), leptin levels in obese patients were found to be higher
than that of nonobese patients, as we also found in the present
study. Since leptin levels may be affected by age, we included
only patients <65 years of age, and the average age of the obese
group was signiﬁcantly lower than that of the nonobese group.
This situation may indicate earlier development of CHD in the
obese. In other studies, obesity has not been found to correlate
with leptin levels in people over the age of 65.19,20 As individuals
age, leptin levels fall. Ostlund et al.5 found a negative correlation
between age and leptin levels, independent of body fat, in
patients between the ages of 18 and 80 (mean (SD) 52.8 (15.8)
years). This indicates that plasma leptin levels in people over 65
are expected to be signiﬁcantly lower than that of the people
under the age of 65. A decrease in leptin levels produced by
adipose tissue and/or an increase in plasma leptin clearance
may be responsible for this difference. On the other hand,
certain studies have found a positive correlation between
plasma leptin levels and age.21
In this study, the smoking rate of the obese group was
similar with the nonobese group. Previous studies have shown
that body fat ratio and leptin levels are lower in smokers.22
This may be explained by the fact that total fat mass is lower in
smokers. In addition, leptin resistance has been found to
increase in smokers compared with nonsmokers.22In our study, a positive correlation was found between
leptin levels and BMI, WC, HC, and WHR. Previous studies
reported contradictory results; positive20,23 and negative4,19,24
correlations were obtained between leptin levels and WHR.
The positive correlation between leptin levels and WHR is
predominantly seen in males and the negative correlation is
predominantly detected in females. This gender-related
difference may be explained by the greater abundance of
subcutaneous fat tissue in females and of visceral fat tissue in
males. In addition, previous studies have found higher leptin
secretion in subcutaneous fat tissue than visceral fat tissue.25
In one study, WC was found to be a better measure of visceral
adipose tissue than WHR.26 This study supports these previous
studies.
Hyperleptinemia may co-occur with other atherosclerosis
risk factors associated with obesity. This study evaluated the
total CH, HDL-CH, LDL-CH, uric acid, and TG levels. Along with
the signiﬁcant difference in leptin levels between obese and
nonobese groups, signiﬁcant differences in LDL-CH, total CH,
HDL-CH, uric acid, and TG levels were also found between
obese and nonobese groups. In a study conducted by
Piestrzeniewicz et al.,27 TG, uric acid, and fasting blood glucose
levels showed signiﬁcant differences between obese and
nonobese groups.
In this study, the relationship of leptin levels with CV risk
factors (SBP, DBP, fasting blood glucose, total CH, HDL-CH, LDL-
CH, and TG levels) between obese and nonobese groups was
evaluated. DBP was the only one of these factors that was
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from other studies support this ﬁnding. Dunbar et al.28
observed that when rats were infused with intracerebroven-
tricular leptin, blood pressure increased, along with the
sympathetic activity. A study investigating the correlation
between leptin and high blood pressure in humans found that
hyperleptinemia leading to insulin intolerance might be
responsible for the pathogenesis of primary hypertension.29
Several studies have shown positive correlations between
plasma leptin and TG levels.24,30 On the other hand, no
correlation has been detected between plasma leptin and LDL-
CH levels.19,20 The relationship between plasma leptin and
HDL-CH is controversial. While a negative correlation was
found between plasma leptin and HDL-CH levels in some
studies,30 the others failed to show such a correlation.4,19 As a
result, the correlation between the known lipid risk factors for
CHD and leptin remains in question. In our study, no
correlation was found between leptin and lipid parameters.
In addition, the positive correlation found between leptin
levels and uric acid31 and fasting blood glucose levels, which
are known to be CHD risk factors, has not been observed in this
study. This may be due to the relatively low number of patients
in this study, compared to other studies.
Inﬂammation plays an important role in all stages of
atherosclerosis,32 and CRP, interleukin 6 (IL-6), tumor necrosis
factor (TNF)-alpha, adiponectin and resistin, mediators of
inﬂammation, are secreted from adipose tissue in response to
leptin.33 Although CRP's role in chronic inﬂammatory pro-
cesses is not its only function, it is known to lead to the
development of atherosclerosis.34 It has also been shown that
leptin plays a part in reacting to certain acute stress
situations.35 Increases in serum leptin levels have been
observed within 24 h of acute myocardial infarct.35,36 Pro-
inﬂammatory cytokines may show an increase along with
leptin; in other words, leptin may have a role in the
development of inﬂammation under acute stress.36 This
relationship may be explained by the similarities between
the IL-6 receptor and the leptin receptor.37 In our study, leptin
and CRP levels in obese and nonobese male patients who had
AMI were checked and the correlation between them was
investigated. No correlation was found between leptin and CRP
levels. This was in contrast to several previous studies that
found a positive correlation between leptin and CRP levels in
obese and nonobese patients, both in healthy individuals and
in patients with coronary artery disease.21,38 However, the
results supported those of Fujimaki,39 who also failed to ﬁnd
such a positive correlation. These different results may be
related to the differences in patients' reactions to stress and
inﬂammation.
5. Conclusion
This study indicated leptin levels of obese male patients <65
years of age with AMI to be higher than that of the nonobese
subjects. Leptin was positively correlated with WC, HC, WHR,
and BMI, in both obese and nonobese patients.
Our search for correlation between leptin and several CV
risk factors yielded a positive correlation only between DBP
and leptin. Opinions from different research groups vary onthe correlation between CV risk factors and leptin. These
differences may stem from the ethnicity, age, the existence
and stage of obesity, co-morbid diseases, insulin intolerance,
leptin intolerance, and other such factors of the individuals.
This study shows that obese males with AMI have higher
levels of leptin compared with nonobese males. This may lead
us to conclude that leptin level may represent a useful tool for
evaluating CV risks in obese males. However, the results also
indicate that leptin level measurement, which is relatively
expensive, has no signiﬁcant advantage over evaluating CV
risks through assessment of obesity using anthropometric
measurements.
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